Fig. 6: Effective combination therapies in CRISPR-modified fusion models.
From: Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
a The half maximal inhibitory concentrations (IC50s) of osimertinib and indicated drugs in parental PC-9 and in single clones from CRISPR-modified PC-9 models, after 72 h of treatment. For each fusion model, we used two single clones. Each dot indicates the mean of biological triplicate data. b Synergistic inhibitory effects of osimertinib and individual drugs in CRISPR-modified PC-9 models as shown by Combenefit (n = 2 biological replicates, mean). Pseudo-color represents synergy effects. c Western blot analyses following 48 h of treatment with 10 nM trametinib or 0.5 μM of other drugs, as indicated. d Proliferation of cells (top) and induction of caspase-3/7 (bottom) evaluated by Incucyte live-cell imaging (n = 3 biological replicates, mean ± s.d.). Source data of a–d are provided as a Source Data file.
